文献速递免疫规划慢病防控与筛查

癌症患者对Covid-19疫苗接种的体液免疫应答——ANRS0001S COV-POPART研究结果

Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART study.
PubMed 文献 · Vaccine · 2025-08-22

该研究纳入183例癌症患者和1173名健康对照,比较基础免疫系列后及加强针后抗SARS-CoV-2 IgG抗体应答。癌症患者基础免疫后抗体水平较低,但加强针后1个月和6个月应答率与对照相当,支持癌症患者接种加强针的获益。

要点

  • 癌症患者基础免疫后抗Spike IgG几何平均滴度低于对照(132.4 vs 332.7 BAU/mL,P<0.0001)。
  • 加强针后1个月和6个月,癌症患者与对照抗体滴度无显著差异。
  • 结果支持癌症患者接种加强针的获益。

核心结论

  • 癌症患者在加强针后1个月和6个月的应答率与对照相当,结果支持癌症患者接种加强针的获益。

研究设计与样本

  • 法国国家前瞻性Covid-19疫苗队列研究(ANRS0001S COV-POPART),纳入年龄≤75岁、完成两剂基础免疫系列并接种加强针的参与者,排除SARS-CoV-2感染者。
  • 共纳入183例癌症患者和1173名对照。
  • 最常见癌症为乳腺癌(37.2%)和肺癌(17.5%)。

主要发现

  • 基础免疫系列后,癌症患者抗Spike IgG几何平均滴度低于对照(132.4 vs 332.7 BAU/mL,P<0.0001)。
  • 加强针后1个月,癌症患者与对照抗Spike IgG几何平均滴度无显著差异(2146.1 vs 1841.3 BAU/mL,P=0.16)。
  • 加强针后6个月,癌症患者与对照抗Spike IgG几何平均滴度无显著差异(602.0 vs 574.4 BAU/mL,P=0.80)。
  • 针对原始株、Delta和Omicron变异株的特异性中和抗体水平证实上述结果。
  • 癌症患者年龄较对照更大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cancer, whose immune responses to vaccines are commonly weaker than those of the general population, are recommended a booster dose after two initial doses of Covid-19 vaccine. Our objective was to compare the humoral immunogenicity of Covid-19 vaccines in patients with cancer compared to healthy adults (control group) after primary vaccine series and after a booster dose. METHODS: We included participants aged ≤75 and vaccinated with two doses in the primary vaccine series and a booster, from the French national prospective Covid-19 vaccine cohort study (ANRS0001S COV-POPART) and excluded those with SARS-CoV-2 infection. Percentage of responders, geometric mean titers (GMT) of anti-SARS-CoV-2 IgG antibodies (ELISA) and specific neutralizing antibodies against original strain, Delta and Omicron variants of concern, were estimated one month after the primary vaccine series, then one month and six months after a booster dose. RESULTS: We included 183 patients with cancer and 1173 controls. The most frequent cancers were breast (37.2 %) and lung cancer (17.5 %). Patients with cancer were older and had lower anti-Spike IgG levels after the primary vaccine series (GMT = 132.4 vs 332.7 BAU/mL, P < 0.0001), but they developed similar response at one month (GMT = 2146.1 vs 1841.3 BAU/mL], P = 0.16) and six months after booster (602.0 vs 574.4 BAU/mL, P = 0.80). Neutralizing antibodies levels confirmed these results. CONCLUSION: Patients with cancer have comparable response rates to controls one month and six months after a booster dose. Our results support the benefit of a booster dose in patients with cancer.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Luong Nguyen LB, Magloire L, François A, et al. Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART study. Vaccine. 2025. PMID: 40848673. doi:10.1016/j.vaccine.2025.127633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。